You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Understand why the Medtronic paclitaxel coated PTCA balloon is an effective treatment option for in-stent restenosis, de novo lesions, and small vessels.Download brochure
Watch an animation to see why Prevail™ drug-coated balloon offers the performance you want for treating complex lesions during percutaneous coronary interventions.1
Prevail™ drug-coated balloon offers the performance you want for treating complex lesions during percutaneous coronary interventions.1
Superior deliverability — deliberately designed to maximise pushability.2
Rapid absorption of paclitaxel facilitated by biocompatible urea excipient.1,3
Excellent safety and efficacy as demonstrated in the IN.PACT™ Falcon Clinical Program and confirmed in the PREVAIL™ Study.4
PowerTrac™ technology and hydrophilic coating enable superior deliverability
FreePac coating combines two proven components that work together:
The PREVAIL™ Study adds to the clinical legacy of the IN.PACT™ Falcon Clinical Program.
|Balloon Length (mm)|
|Balloon Diameter (mm)||10||15||20||25||30|
™Third-party brands are trademarks of their respective owners.
99% improved push force compared to IN.PACT™ Falcon DCB.
IN.PACT™ Falcon DCB and Prevail™ DCB use the same FreePac™ coating. PREVAIL Study did not have powered endpoints.
Prevail Instructions for Use.
Compared with IN.PACT Falcon DCB, SeQuent®* Please NEO DCB*, Agent™* DCB, and MagicTouch™* DCB. Deliverability defined as pushability. Based on bench test data, 2020. Bench test data may not be indicative of clinical performance.
Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol. August 1994;5(2):125-37.
Latib A, et al. PREVAIL Study 12-month results. Results presented at PCR 2020.
Virmani R. Arterial wall response to drug-coated balloons. Confluence. September 2016;13:15-19.
Cremers B, Clever Y, Schaffner S, et al. Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. Minerva Cardioangiol. October 2010;58(5):583-8.